![M. Boyd](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
M. Boyd
Plus aucun poste en cours
Fortune : 76 295 $ au 31/05/2026
Profil
M.
Cantey Boyd is an Independent Director at Kiniksa Pharmaceuticals International Plc since 2024.
Former positions include Director at Aquinox Pharmaceuticals, Inc., Director and Independent Director at Neoleukin Therapeutics, Inc., and Principal at Baker Bros.
Advisors LP.
Education includes undergraduate studies at Brown University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0% | 06/04/2026 | 1 577 ( 0% ) | 76 295 $ | 31/05/2026 |
Postes actifs de M. Boyd
| Sociétés | Poste | Début |
|---|
Anciens postes connus de M. Boyd
| Sociétés | Poste | Fin |
|---|---|---|
| NEUROGENE INC. | Directeur/Membre du Conseil | - |
Neoleukin Therapeutics, Inc. /old/
 Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Develops medicines that transform lives | Directeur/Membre du Conseil | - |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Directeur/Membre du Conseil | - |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Analyst-Equity | - |
Formation de M. Boyd
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance BBA pursues a fundamentally driven approach to life sciences investing. The firm typically takes large, concentrated positions in the securities of life sciences companies with the potential for significant value creation over the long-term. They focus on public securities, but may, from time to time, recommend investments in private companies, life sciences and related healthcare intellectual property, royalty streams or other non-public investment opportunities. | Finance |
Brown University
 Brown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in identification and development of therapeutics for inflammatory diseases and cancer | Health Technology |
Neoleukin Therapeutics, Inc. /old/
Neoleukin Therapeutics, Inc. /old/ Pharmaceuticals: MajorHealth Technology Develops medicines that transform lives | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
